Your browser doesn't support javascript.
loading
Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma.
Sekely, Angela; Bernstein, Lori J; Campbell, Kristin L; Mason, Warren P; Laperriere, Normand; Kalidindi, Navya; Or, Rosemarylin; Ramos, Ronald; Climans, Seth A; Pond, Gregory R; Ann Millar, Barbara; Shultz, David; Tsang, Derek S; Zadeh, Gelareh; Edelstein, Kim.
Afiliação
  • Sekely A; Graduate Department of Psychological Clinical Science, University of Toronto, Toronto, Ontario, Canada.
  • Bernstein LJ; Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Campbell KL; Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Mason WP; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
  • Laperriere N; Department of Physical Therapy, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Kalidindi N; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Or R; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Ramos R; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Climans SA; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Pond GR; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Ann Millar B; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Shultz D; Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, Ontario, Canada.
  • Tsang DS; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Zadeh G; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Edelstein K; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Neurooncol Pract ; 10(1): 89-96, 2023 Feb.
Article em En | MEDLINE | ID: mdl-36659968
ABSTRACT

Background:

In addition to poor survival rates, individuals with glioblastoma (GBM) are at risk of neurocognitive impairment due to multiple factors. This study aimed to characterize neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in newly diagnosed GBM patients; and to examine whether neurobehavioral symptoms, fatigue, sleep, and depressive symptoms influence neurocognitive performance.

Methods:

This study was part of a prospective, inception cohort, single-arm exercise intervention in which GBM patients underwent a neuropsychological assessment shortly after diagnosis (median 4 weeks; ie, baseline) and 3, 6, 12, and 18 months later, or until tumor progression. Here, we present baseline data. Forty-five GBM patients (mean age = 55 years) completed objective neurocognitive tests, and self-report measures of neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms.

Results:

Compared to normative samples, GBM patients scored significantly lower on all neurocognitive tests, with 34 (76%) patients exhibiting neurocognitive impairment. Specifically, 53% exhibited impairment in memory retention, 51% in executive function, 42% in immediate recall, 41% in verbal fluency, and 24% in attention. There were high rates of clinically elevated sleep disturbance (70%), fatigue (57%), depressive symptoms (16%), and neurobehavioral symptoms (27%). A multivariate regression analysis revealed that depressive symptoms are significantly associated with neurocognitive impairment.

Conclusions:

GBM patients are vulnerable to adverse outcomes including neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms shortly after diagnosis, prior to completing chemoradiation. Those with increased depressive symptoms are more likely to demonstrate neurocognitive impairment, highlighting the need for early identification and treatment of depression in this population.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Neurooncol Pract Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Neurooncol Pract Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá